![David Schilansky](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David Schilansky
Directeur Financier/CFO chez
SCANCELL HOLDINGS PLC
Profil
David S.
Schilansky is the founder of Home Biosciences SAS, founded in 2019, where the title held is Chairman & Chief Executive Officer.
Mr. Schilansky is also the founder of One Biosciences SAS. Mr. Schilansky is Chief Financial Officer at Scancell Holdings Plc since 2026.
Former positions include Chief Executive Officer at Ariceum Therapeutics GmbH from 2025 to 2026; Director-Investor Relations at Ipsen International GmbH; Independent Non-Executive Director at Lysogene SA from 2016 to 2022; Head-Investor Relations at Tercica, Inc.; Group Chief Financial Officer at Ipsen SA from 2009 to 2011; Head-Investor Relations at Vantiva Usa Shared Services, Inc. from 2003 to 2006; CFO & Principal Financial & Accounting Officer at DBV Technologies SA from 2014 to 2015; Chief Financial Officer at Ipsen Pharma SAS. Education includes graduate degrees from Imperial College London and Université Paris Dauphine-PSL.
Postes actifs de David Schilansky
| Sociétés | Poste | Début |
|---|---|---|
| SCANCELL HOLDINGS PLC | Directeur Financier/CFO | 24/04/2026 |
One Biosciences SAS
 One Biosciences SAS BiotechnologyHealth Technology Provides single-cell technology research and development services | Fondateur | 01/07/2020 |
Home Biosciences SAS
 Home Biosciences SAS BiotechnologyHealth Technology Operates as biotechnology company | Directeur Général | 01/01/2019 |
Anciens postes connus de David Schilansky
| Sociétés | Poste | Fin |
|---|---|---|
Ariceum Therapeutics GmbH
 Ariceum Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Develops novel targeted radiopharmaceuticals for treatment of cancer | Directeur Général | 01/01/2026 |
| LYSOGENE | Directeur/Membre du Conseil | 24/06/2022 |
| DBV TECHNOLOGIES | Directeur Financier/CFO | - |
| IPSEN | Directeur Financier/CFO | 01/12/2011 |
Vantiva Usa Shared Services, Inc.
 Vantiva Usa Shared Services, Inc. Electronics/AppliancesConsumer Durables Manufactures electronic appliances and products | Investor Relations Contact | - |
Formation de David Schilansky
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
46
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology Develops new therapeutics for endocrine system disorders | Health Technology |
Ipsen SA
 Ipsen SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Imperial College London
 Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ipsen International GmbH
 Ipsen International GmbH Industrial MachineryProducer Manufacturing Manufactures and distributes furnaces and plant systems | Producer Manufacturing |
Vantiva Usa Shared Services, Inc.
Vantiva Usa Shared Services, Inc. Electronics/AppliancesConsumer Durables Manufactures electronic appliances and products | Consumer Durables |
DBV Technologies SA
 DBV Technologies SA Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that focuses on changing the field of immunotherapy | Health Technology |
Université Paris Dauphine-PSL
 Université Paris Dauphine-PSL Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Scancell Holdings Plc
 Scancell Holdings Plc BiotechnologyHealth Technology Develops therapeutic cancer vaccines | Health Technology |
Ipsen Pharma SAS
 Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Lysogene SA
 Lysogene SA BiotechnologyHealth Technology Engages in research and clinical development of gene therapy for neurodegenerative disorders | Health Technology |
One Biosciences SAS
One Biosciences SAS BiotechnologyHealth Technology Provides single-cell technology research and development services | Health Technology |
Home Biosciences SAS
Home Biosciences SAS BiotechnologyHealth Technology Operates as biotechnology company | Health Technology |
Ariceum Therapeutics GmbH
Ariceum Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Develops novel targeted radiopharmaceuticals for treatment of cancer | Health Technology |
Choisissez Zonebourse 
